



Image

1634

PATENT
ATTORNEY DOCKET NO. 50026/012004

Certificate of Mailing: Date of Deposit: February 19, 2004

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as **first class mail** with sufficient postage on the date indicated above and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Christine M. Colbert

Printed name of person mailing correspondence

Christine M. Colbert

Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Keiya Ozawa et al.

Art Unit: 1634

Serial No.: 09/905,591

Examiner: B. Sisson

Filed: July 13, 2001

Customer No.: 21559

Title: GENE THAT IMPARTS SELECTIVE PROLIFERATIVE ACTIVITY

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT

Applicants submit the references listed on the attached form PTO-1449, copies of which are enclosed.

Submission of this statement is not a representation that a search has been made, nor is information included in this statement an admission that the information is material to patentability.

This statement is being filed after a first Office Action on the merits, but before

02/26/2004 SZWDIE1 00000063 09905591

01 FC:1806


180.00 OP

receipt of a final Office Action or a Notice of Allowance. A check for \$180.00 in payment of the late submission fee of 37 C.F.R. § 1.17(p) is enclosed.

If there are any other charges or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date: 19 FEBRUARY 2004



James D. DeCamp, Ph.D.
Reg. No. 43,580

JAN M. FITZGERALD, Ph.D.
Reg. No. 52,290

Clark & Elbing LLP
101 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045



SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))				Attorney Docket No. 50026/012004 Serial No. 09/905,591 Applicant Keiya Ozawa et al. Filing Date July 13, 2001 Group 1634 IDS Filed February 19, 2004		
U.S. PATENTS						
Examiner's Initials	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date (If Appropriate)
	5,686,281	Nov. 11, 1997	Roberts			
	5,747,292	May 5, 1998	Greenberg et al.			
	6,416,998	Jul. 9, 2002	O'Malley et al.			
FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION						
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)						
	Anderson; "Human Gene Therapy" <i>Nature</i> 392(Supp.):25-30 (1998).					
	Cheok, "Cancer Fears Cast Doubts on Future of Gene Therapy" <i>Nature</i> 421:678 (2003).					
	Cui et al., "Inhibitory Effect of a Soluble Transforming Growth Factor β Type II Receptor on the Activation of Rat Hepatic Stellate Cells in Primary Culture" <i>Journal of Hepatology</i> 39:731-737 (2003).					
	Finer et al., "kat: A High-Efficiency Retroviral Transduction System for Primary Human T Lymphocytes" <i>Blood</i> 83:43-50 (1994).					
	Juengst, "What Next for Human Gene Therapy" <i>BMJ</i> 326:1410-1411 (2003).					
	Kakuta et al., "Inhibition of B16 Melanoma Experimental Metastasis by Interferon- γ through Direct Inhibition of Cell Proliferation and Activation of Antitumour Host Mechanisms," <i>Immunology</i> 105:92-100 (2002).					
	Kmiec "Gene Therapy" <i>American Scientist</i> 87:240-247 (1999).					
	Marcinkowska and Więdołcha "Steroid Signal Transduction Activated at the Cell Membrane: from Plants to Animals," <i>Acta Biochimica Polonica</i> 49(3):735-745 (2002).					
	Maruyama et al., "Proliferation and Erythroid Differentiation through the Cytoplasmic Domain of the Erythropoietin Receptor," <i>The Journal of Biological Chemistry</i> , 269(8):5976-5980 (1994).					
	Morgenstern and Land "Advanced Mammalian Gene Transfer: High Titre Retroviral Vectors with Multiple Drug Selection Markers and a Complementary Helper-Free Packaging Cell Line" <i>Nucleic Acids Research</i> 18:3587-3596 (1990).					
EXAMINER				DATE CONSIDERED		
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.						



SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		Attorney Docket No. Serial No. Applicant Filing Date Group IDS Filed		50026/012004 09/905,591 Keiya Ozawa et al. July 13, 2001 1634 February 19, 2004	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)							
(37 C.F.R. § 1.98(b))							
U.S. PATENTS							
Examiner's Initials	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date (If Appropriate)	
FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION							
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)	
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)							
	O'Farrell et al., "IL-10 Inhibits Macrophage Activation and Proliferation by Distinct Signaling Mechanisms: Evidence for Stat3-Dependent and -Independent Pathways," <i>The EMBO Journal</i> 17(4):1006-1018 (1998).						
	Roussel et al., "Colony-Stimulating Factor 1-Mediated Regulation of a Chimeric c-fms/v-fms Receptor Containing the v-fms-Encoded Tyrosine Kinase Domain" <i>Proc. Natl. Acad. Sci. USA</i> 85:5903-5907 (1988).						
	Verma and Somia, "Gene Therapy-Promises, Problems and Prospects," <i>Nature</i> 389:239-242 (1997).						
	Wang et al., "Yeast Two-Hybrid System Demonstrates that Estrogen Receptor Dimerization Is Ligand-Dependent <i>in Vivo</i> ," <i>The Journal of Biological Chemistry</i> , 270(40):23322-23329 (1995).						
	Wimmel et al., "Autocrine Growth Inhibition by Transforming Growth Factor β -1 (TGF β -1) in Human Neuroendocrine Tumour Cells," <i>Gut</i> 52:1308-1316 (2003).						
EXAMINER				DATE CONSIDERED			
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.							